Endpoints News

BioNTech to exit Singapore site		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M Tue W Th F

7 April, 2026

John Carroll’s R&D 15 report is back — and this year, he’s bringing some of the industry’s top research chiefs into the conversation to break down what the data means, what’s shifting, and where biopharma R&D is headed. Join us to find out what comes next.

presented by

Forge Biologics A Member of Ajinomoto Bio-Pharma Services

Presenting Your Gene Therapy Manufacturing Plan to Investors: What They Expect in 2026 and How to Deliver It

news

Sanofi bispecific sails through asthma, sinusitis trials but disappoints in eczema

BioNTech to shutter Singapore HQ after 'comprehensive review'

Proposed FDA budget aligns Makary, Trump behind rivaling China biotech

Apr 29

12:00 pm ET

From genotype to outcomes: Real-world evidence in glomerular diseases

in case you missed it

Neurocrine will pay $2.9B for Soleno and its Prader-Willi medicine

Amgen's Phase 3 success sets up an eye drug showdown with Viridian

Takeda ends partnership with Denali amid restructuring

News Briefing

Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial

China's Syneron raises $150M for peptides, adding to last year's $100M

Stipple Bio launches with $100M to find more precise targets on cancer proteins

Why some cancer-fighting immune cells lose their strength inside tumours

Sanofi reported mid-stage data this morning for the IL-13 and TSLP bispecific inhibitor lunsekimig. The French pharma envisions the drug not only as a potential successor to Dupixent (which blocks IL-13 and IL-4) but also to AstraZeneca's Tezspire (which targets TSLP only). The details from Ayisha Sharma are here.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com